WO2025167503 - ANTI-SEZ6/B7H3 ANTIBODIES AND USES THEREOF

National phase entry is expected:
Publication Number WO/2025/167503
Publication Date 14.08.2025
International Application No. PCT/CN2025/072605
International Filing Date 15.01.2025
Title **
[English] ANTI-SEZ6/B7H3 ANTIBODIES AND USES THEREOF
[French] ANTICORPS ANTI-SEZ6/B7H3 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
HAO, Kunying
LI, Peiran
SHANG, Chengzhang
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2024/075962   05.02.2024   CN
PCT/CN2024/105500   15.07.2024   CN
PCT/CN2024/120074   20.09.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3820
EPO Filing, Examination, Granting47504
Japan Filing, Examination, Granting3634
South Korea Filing, Examination, Granting5271
USA Filing, Examination, Granting19590
MasterCard Visa
Total: 79,819
Contact Us
Abstract[English] This disclosure provides anti-SEZ6 antibodies or antigen binding fragments thereof, anti-B7H3 antibodies or antigen binding fragments thereof, antigen-binding protein constructs (e.g., bispecific antibodies or antigen-binding fragments thereof) that specifically bind to two different antigens (e.g.,SEZ6 and B7H3), and antibody drug conjugates.[French] La présente divulgation concerne des anticorps anti-SEZ6 ou des fragments de liaison à l'antigène de ceux-ci, des anticorps anti-B7H3 ou des fragments de liaison à l'antigène de ceux-ci, des constructions de protéine de liaison à l'antigène (par exemple, des anticorps bispécifiques ou des fragments de liaison à l'antigène de ceux-ci) qui se lient de manière spécifique à deux antigènes différents (par exemple, SEZ6 et B7H3), et des conjugués anticorps-médicament.

Rejoining the server...